ApoGen Biotechnologies Garners $7,000,000 Series A Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=13515bec-6b32-4800-b238-9098e216930a - Date
12/13/2016 - Company Name
ApoGen Biotechnologies - Mailing Address
1616 Eastlake Ave E. Seattle, WA 98102 USA - Company Description
ApoGen Biotechnologies, Inc. is a biotechnology company focused on the development of a new class of therapeutics targeting drivers of cancer genomic mutation. ApoGen is building upon technologies developed at the University of Minnesota to develop drugs that block a key pathway that causes drug resistance. - Website
http://www.apogenbiotech.com - Transaction Type
Venture Equity - Transaction Amount
$7,000,000 - Transaction Round
Series A - Proceeds Purposes
We are excited to invest Accelerator’s unique startup resources to potentially develop these promising technologies for cancer patients in need. - M&A Terms
- Venture Investor
AbbVie Biotech Ventures - Venture Investor
Alexandria Venture Investments - Venture Investor
ARCH Venture Partners - Venture Investor
Johnson & Johnson Development Corporation - Venture Investor
WRF Capital - Venture Investor
WuXi PharmaTech
